摩根士丹利-海普瑞(09989):非全资子公司HighTide主导资产Ⅲ期试验达主要终点-Shenzhen Hepalink Pharmaceutical:Non-wholly Owned Subsidiary HighTide Achieves Primary Endpoint in Phase Ⅲ Trial for Lea-20251202【9页】

发表回复

后才能评论